Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China
This study serves as a significant supplement to the current literature regarding the accepting foreign clinical data policy and innovation investment, providing valuable insights for policymakers and R&D decision-makers in the pharmaceutical sector.
Authors
- Jingjing Huang (ORCID: https://orcid.org/0000-0001-8071-1715)
- Minhua Jiang (ORCID: https://orcid.org/0000-0002-8729-5344)
- Yibo Fan (ORCID: https://orcid.org/0000-0001-7589-4158)
- Su Wang (ORCID: https://orcid.org/0000-0001-8894-4003)
- Yuwen Chen (ORCID: https://orcid.org/0000-0003-1804-4653)
Institutions
- Shenyang Pharmaceutical University (CN)
- Shanghai University of Medicine and Health Sciences (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fpubh.2025.1512148
- Primary Topic
- Innovation Policy and R&D
- Type
- article
- Field-Weighted Citation Impact
- 0.00